Min‐Hee Ryu

机构：University of Ulsan · ORCID：0000-0002-1033-1263

发表论文 514 篇 · 总被引 19189 次 · h-index 59

代表论文

• Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC (2025 · Journal of Hepatology · 被引 136)
• Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study (2025 · Journal of Clinical Oncology · 被引 18)
• Trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM) + paclitaxel (PTX) in second-line treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) unresectable/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary analysis of the randomized, phase 3 DESTINY-Gastric04 study. (2025 · Journal of Clinical Oncology · 被引 10)
• Predictive value of EBV-positivity in patients with gastric cancer treated with first-line nivolumab plus chemotherapy (2025 · Gastric Cancer · 被引 8)
• Artificial intelligence-based prediction of claudin 18.2 expression and immune phenotype to guide treatment decisions in patients with gastric cancer. (2025 · Journal of Clinical Oncology · 被引 4)
• Nivolumab Plus Chemotherapy versus Placebo Plus Chemotherapy in Korean Patients with HER2-Negative, Untreated, Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer: Subgroup Analysis of a Randomized, Multicenter, Double-Blind Phase 3 Trial (ATTRACTION-4) (2025 · Cancer Research and Treatment · 被引 3)